Table 4 Validations of top 50 predicted drug indications for AD and PD, ordered by ranking

Rasagiline

Weinreb et al. Neurotherapeutics. (6)1:163–74. (2009) [70]

Dextroamphetamine

Parkes et al. J Neurol Neurosurg Psychiatry. 38(3):232–7 (1975) [83]

Interferons

Grimaldi et al. J Neuroinflammation. 11:30 (2014) [71]

Orphenadrine

Bersani et al. Clin Neuropharmacol. 13(6):500–6 (1990) [84]

Calcium

Woods et al. Adv Exp Med Biol. 740:1193–217 (2012) [72]

Quinacrine

Tariq et al. Brain Res Bull. 54(1):77–82 (2001) [85]

Dovitinib

Li et al. Medical Hypotheses. (80)4:341–44. (2013) [73]

Atomoxetine

Weintraub et al. Neurology. 75(5):448–55 (2010) [86]

Somatropin Recombinant

Ling et al. Growth Horm IGF Res. (17)4:336–41 (2007) [74]

Aripiprazole

De Deyn et al. Expert Opin. Pharmacother. (14)4:459–74 (2013) [75]

Clozapine

Tariot et al. Clin Geriatr Med. (17)2:359–76 (2001) [76]

Quercetin

Ansari et al. J Nutr Biochem. 20(4):269–75 (2009) [77]

Flavopiridol

Pallàs et al. Med Hypotheses. 64(1):120–3 (2005) [78]

Sunitinib

Grammas et al. J Alzheimers Dis. 40(3):619–30 (2014) [79]

Risperidone

Katz et al. Int J Geriatr Psychiatry. (60)2:107–15 (2007) [80]

Genistein

Valles et al. Brain Res. 1312:138–44 (2010) [81]

Dasatinib

Dhawan et al. J Neuroinflammation. 9:117 (2012) [82]